Background: Electrocardiographic (ECG) left ventricular hypertrophy (LVH) is a risk factor for cardiovascular events and the incidence of LVH increases with age. However, few studies have assessed risks associated with LVH in elderly hypertensive patients.
eft ventricular hypertrophy (LVH) is present in 30% of patients with hypertension 1 and is the next strongest risk factor for cardiovascular events after age. 2 The incidence of hypertension 3, 4 and LVH 5 are known to increase with age. Many studies have reported that LVH diagnosed on electrocardiography (ECG) or echocardiography is a predictor of cardiovascular events. 6-8 However, few studies have examined the implications of LVH in elderly patients. 9, 10 Whether LVH on ECG is a risk factor for cardiovascular events in elderly hypertensive patients remains a matter of debate. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS) studied optimal blood pressure in elderly hypertensive patients. 11 We performed a subanalysis of data from JATOS to clarify whether LVH is associated with cardiovascular events in elderly hypertensive patients.
Methods
JATOS was a prospective, randomized, open, blinded endpoint (PROBE) study designed to compare the combined incidence of cardiovascular events (stroke, cardiovascular disease, and renal failure), the primary endpoint, between a strict treatment group (target systolic blood pressure (SBP), <140 mmHg) and a mild treatment group (target SBP, ≥140 to <160 mmHg) in 4,418 elderly hypertensive patients who received 2 years
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of antihypertensive treatment with efonidipine, a longacting calcium antagonist, as a baseline drug (University Hospital Medical Information Network registration number, UMIN000001021). Many general practitioners in Japan participated in the study and the data were sent to a central office for collation and analysis. The protocol was approved by the ethics committee of the Japan Physicians Association and by the executive committee of the Japanese Society of Hypertension. The detailed methods and main results have been reported previously 11 and are described briefly below.
The study group comprised non-hospitalized patients 65-85 years old who had essential hypertension with SBP of ≥160 mmHg during the run-in period. Patients were excluded from the study if they had any of the following conditions: previous treatment with efonidipine; diastolic blood pressure (DBP) ≥120 mmHg; secondary hypertension; history of stroke or myocardial infarction within the past 6 months; history of coronary angioplasty; angina pectoris requiring hospitalization; heart failure New York Heart Association (NYHA) class II or higher; sustained arrhythmia such as atrial fibrillation, aortic dissection, or aortic aneurysm; arterial occlusive disease; hypertensive retinopathy; elevated hepatic enzymes; poorly controlled diabetes mellitus with fasting blood glucose concentration ≥200 mg/dl or hemoglobin A1c concentration ≥8%; renal impairment (serum creatinine concentration, >1.5 mg/dl); malignant disease; or collagen disease. Written informed consent was obtained from all participating patients. The attending physicians sent patient registration data to the central office by fax. Treatment was randomly assigned to registered patients by computer. The enrollment period was 1 April, 2001 to 31 December, 2002. Treatment was completed on 31 December, 2004. The attending physicians adjusted the doses of efonidipine and other drugs (excluding calcium antagonists) to reach the assigned targeted blood pressure within about 3 months after the start of treatment. All participants were examined at 2-to 4-week intervals. Physical findings such as blood pressure and pulse rate, adverse events, and the presence or absence of complications were assessed at each visit. General blood tests were performed at 6-month intervals. During the run-in period, chest radiography and ECG were performed and recorded as baseline data. These examinations were repeated at the end of the study.
Definition of LVH
All ECGs recorded by the attending physicians were sent to the central office. Apart from the diagnosis of cardiac hypertrophy by the attending physicians at enrollment, 2 cardiologists who were blinded to the treatment assignments and the time course of blood pressure, re-measured and doublechecked all data on the baseline 12-lead ECGs. SokolowLyon voltage, an index of LVH, was calculated as the sum of the height of the S wave in lead V1 and the R wave in lead V5 (SV1+ RV5). 4, 12 To simplify definitions and permit the results to be extrapolated to a broad range of patients, LVH was defined on the basis of voltage values alone, which can be readily analyzed statistically, irrespective of strain patterns and left-axis deviation. We examined the relationship between LVH and the incidence of cardiovascular events in 3,230 patients in whom SV1+ RV5 could be measured on baseline ECGs. For data analysis, SV1+ RV5 was considered a continuous variable as well as a categorical variable, using threshold values of 35 mm (3.5 mV), 38 mm (3.8 mV), or 40 mm (4.0 mV) to define LVH. The incidences of cardiovascular events were then compared between the groups.
Statistical Analysis
The characteristics of the patients at baseline were compared using the chi-squared test for proportional data and Student's t-test for continuous variables. A univariate Cox regression analysis was performed to evaluate the relationship between LVH on ECG and the incidence of cardiovascular events. LVH was defined using SV1+ RV5 as a continuous variable as well as a categorical variable, with voltage threshold values of 35 mm (≤35 mm, >35 mm) or 40 mm (≤40 mm, >40 mm). We also performed multivariate Cox regression analysis to determine whether the incidence of cardiovascular events was related to the following factors: gender, age, obesity, treatment group, SBP and DBP at study entry, current smoking, diabetes mellitus, dyslipidemia, history of heart disease, history of renal disease, history of stroke, and SV1+ RV5. In this analysis a threshold value of 35 mm was used for SV1+ RV5. Next, SV1+ RV5 was classified into 3 groups: ≤35 mm, >35 to ≤40 mm, and >40 mm. The Kaplan -Meier method was used to estimate the cumulative incidences of cardiovascular events in each group, and a log-rank test was used to compare the cumulative incidences among the groups. Fur- Data are presented as n (%) or mean ± SD. CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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thermore, we evaluated ROC analysis between SV1+ RV5 voltage and incidence of cardiovascular events. Two-sided P-values of less than 0.05 were considered to indicate statistical significance.
Results
Of the 3,230 patients in whom SV1+RV5 could be measured on baseline ECGs, 164 (5.1%) had cardiovascular events and 3,066 (94.9%) did not. Table 1 shows the baseline characteristics of patients with and without cardiovascular events. Mean age was 73.5 years.
Baseline Characteristics
Among patients who developed cardiovascular events, compared to those that did not develop such events, it was observed that male gender, advanced age, current smoking, diabetes mellitus, history of heart disease, renal disease, and history of stroke were significantly greater. SV1+ RV5 was also significantly higher in patients with cardiovascular events (P<0.0001). However, body mass index (BMI), blood pressure, and dyslipidemia did not differ significantly between the groups. Table 2 shows the baseline characteristics with and without LVH as SV1+ RV5 >35 mm. Among patients with LVH, compared to those without, it was observed that male gender, BMI, SBP at study entry, current smoking, dyslipidemia, history of renal disease, and SV1+ RV5 were significantly greater.
Occurrence of Cardiovascular Events
After the start of the study, changes in blood pressure were basically similar between the groups to which patients were assigned according to the presence or absence of LVH (SV1+ RV5 >35 mm). SBP in patients with LVH was significantly higher at 4 time points (2, 4, 5, and 9 months after the start of the study), but from 10 months after the start of the study onward, there was no time point (month) at which a significant difference was observed (Figure 1) . Table 3 shows the results of univariate Cox regression Figure 2 shows forest plots of the results of multivariate Cox regression analysis performed with the presence or absence of cardiovascular events as the response variable and gender, age, obesity, treatment group, SBP and DBP at study entry, current smoking, diabetes mellitus, dyslipidemia, history of heart disease, history of renal disease, history of stroke, and SV1+ RV5 (≤35 mm, >35 mm) as explanatory variables (hazard ratios, P-values, 95% confidence intervals). The hazard ratio for SV1+ RV5 was 1.919, which did not largely differ from the results of univariate Cox regression analysis, indicating that SV1+ RV5 was an independent risk factor for cardiovascular events (P=0.0003). Other significant risk factors for cardiovascular events were male gender, advanced age, current smoking, diabetes mellitus, history of renal disease, and history of stroke. However, obesity, treatment group, SBP and DBP at study entry, dyslipidemia, and history of heart disease were not significant risk factors for cardiovascular events. The cardiovascular events included 95 events of cerebrovascular disease, 49 events of cardiovascular disease, and 17 events of renal impairment. Of these events, only events of cerebrovascular disease were significantly related to SV1+ RV5 (>35 mm) (P=0.0007). Because no patient with renal impairment had a history of heart disease, history of heart disease was excluded from Cox analysis as an explanatory variable. 
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Hazard ratio 0.5 1.0 2.0 4.0 Figure 2 . Multivariate Cox regression analysis was performed with the presence or absence of cardiovascular events as a response variable and with the 13 following factors as explanatory variables: gender, age, obesity, treatment group (strict treatment), systolic blood pressure, diastolic blood pressure, current smoking, diabetes mellitus, dyslipidemia, history of heart disease, history of renal disease, history of stroke, and SV1+ RV5. The results are displayed as forest plots, accompanied by hazards ratios (HRs), P-values, and 95% confidence intervals (CIs). Patients were divided into 2 groups at the threshold value of SV1+ RV5 >35 mm vs ≤35 mm. The incidence of cardiovascular events was compared between the groups. BMI, body mass index.
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In JATOS, it is reported that there was an interaction between patients aged <75 or ≥75 years and strict or mild treatment for the occurrence of cardiovascular events, and cardiovascular events increased in the mild treatment group in patients aged <75 years and in the strict treatment group in patients aged ≥75 years. 11 We investigated whether there was any interaction between patients with or without LVH and strict or mild treatment for the occurrence of cardiovascular events. In patients without LVH (SV1+ RV5 ≤35 mm, n=2,728), the incidence of cardiovascular events was higher in the mild treatment group (64/1,338, 4.78%) than in the strict treatment group (54/1,390, 3 
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LVH (SV1+ RV5 >35 mm, n=502), however, the incidence of cardiovascular events was higher in the strict treatment group (27/248, 10.89%) than in the mild treatment group (19/254, 7.48%). No significant correlation was found in the interaction between LVH and treatment for the combined incidence of cardiovascular events (primary endpoint) (P for interaction = 0.12). Likewise, no significant interaction was found for the incidence of cerebrovascular, cardiovascular, or renal events. Figure 3 shows Kaplan -Meier curves for the cumulative incidence of cardiovascular events according to SV1+ RV5 values of ≤35 mm, >35 to ≤40 mm, and >40 mm, which were adjusted for baseline characteristics. Increasing SV1+ RV5 values were associated with higher incidences of cardiovascular events: a marked increase in events was associated with a value of >40 mm. The incidence of cardiovascular events differed significantly among the 3 groups in the log-rank test (P<0.0001). We also classified the patients into 4 groups (SV1+ RV5 values of ≤35 mm, >35 to ≤38 mm, >38 to ≤40 mm, and >40 mm) and evaluated the number of patients and incidence of cardiovascular events. The number of patients with cardiovascular events was 118/2,728 (4.3%) in the group with SV1+ RV5 of ≤35 mm, 8/131 (6.1%) in the group with >35 to ≤38 mm, 7/113 (6.2%) in the group with >38 to ≤40 mm, and 31/258 (12%) in the group with >40 mm. These results showed that the incidence of events increased sequentially as the electrocardiographic voltage increased. Table 4 shows the results of the ROC analysis between SV1+ RV5 voltage and incidence of cardiovascular events. The optimal cutoff for SV1+ RV5 was 27 mm with a sensitivity of 59.1% and a specificity of 59.0%. The other cutoff values for SV1+ RV5 were 35 mm with a sensitivity of 30.4% and a specificity of 83.9%, 38 mm with a sensitivity of 24.4% and a specificity of 89.1%, and 40 mm with a sensitivity of 22.0% and a specificity of 91.5%.
Discussion
Cohort studies and clinical trials have shown that LVH is a risk factor for cardiovascular events. Many studies have reported that a diagnosis of cardiac hypertrophy on ECG and echocardiography is a predictor of cardiovascular events. 13- 15 The Losartan Intervention For Endpoint (LIFE) study was a double-blind, randomized trial of patients with LVH on ECG. The results indicated that an intervention-based improvement in LVH correlated with a decreased risk of cardiovascular events. 16 However, few previous studies have been done in elderly patients. 9, 10 In the LIFE study, the mean age of the participants was 66.9 years. Sufficient evidence on the clinical significance of LVH as a risk factor in elderly patients is thus lacking.
In the present study, we performed a subanalysis of the JATOS data (mean age of the participants, 73.5 years) to examine the relationship between LVH on ECG and the incidence of cardiovascular events in elderly hypertensive patients. The Sokolow-Lyon voltage was used to diagnose LVH on ECG. 12 This diagnostic criterion is considered less sensitive than other ECG criteria such as the Cornell product (Cornell voltage × QRS duration), and can be affected by factors such as race and obesity. 17, 18 However, the SokolowLyon voltage is straightforward and easy to use; consequently, confirmation of its usefulness in elderly patients would have important diagnostic implications. LVH is usually defined as a Sokolow-Lyon voltage of >35 mm, 12,19 but the LIFE study used a Sokolow-Lyon voltage of >38 mm 16 to increase specificity and confirmed that this value was useful for diagnosis. The Sokolow-Lyon voltage has been reported to differ among different ethnic groups, and is higher in blacks than in whites. In the present study, we examined 2 voltage threshold levels (35 mm and 40 mm) to examine whether a higher threshold voltage could be used for diagnosis. The results of univariate analysis examining the relationship between LVH and the incidence of cardiovascular events showed that the hazard ratio increased by 1.51 times for each increment of 10 mm (=1 mV) in Sokolow-Lyon voltage, when considered a continuous variable. When 35 mm and 40 mm were used as threshold values, the hazard ratio increased by more than 2 times from a voltage of >35 mm, confirming that >35 mm was an appropriate voltage threshold in elderly hypertensive patients ( Table 3) . LVH was therefore defined as a Sokolow-Lyon voltage of >35 mm, and multivariate analysis including other risk factors was performed. LVH was found to be an independent risk factor for cardiovascular events, along with male gender, age, current smoking, diabetes mellitus, history of renal disease, and history of stroke (Figure 2) . The incidence of cardiovascular events was not associated with either SBP or DBP at baseline. In contrast, LVH on ECG was a significant prognostic factor, independent of blood pressure. Our results strongly support previous findings. 13- 15 The occurrence of cardiovascular events was significantly related to SV1+ RV5 (>35 mm) only in patients with cerebrovascular disease (P=0.0007), which is in agreement with the results of subanalysis of CASE-J Trial recently reported by Ueshima et al. 20 In a study of an interaction between the presence/absence of LVH and treatment for the occurrence of cardiovascular events, as with the interaction reported in JATOS, there was no significant difference, but cardiovascular events occurred more commonly in patients with LVH in the strict treatment group. Because the incidence of LVH increases with age, these results recalled the results of JATOS, in which the incidence of events increased in patients aged ≥75 in the strict treatment group. The Kaplan -Meier curves of cardiovascular events according to SV1+ RV5 values of ≤35 mm, >35 to ≤40 mm, and >40 mm showed that increasing severity of LVH was associated with higher incidences of cardiovascular events, which became increasingly divergent among the groups over the 2-year study period (Figure 3) . In the ROC analysis between the SV1+ RV5 voltage and incidence of cardiovascular events, the optimal cutoff value was 27 mm ( Table 4) . Compared with previously reported sensitivity and specificity deduced from echocardiographic LV mass, etc, a sensitivity of 30.4% and a specificity of 83.9% at SV1+ RV5 of 35 mm appeared to be reasonable.
A cohort study of 10,755 Japanese adults among the general population used the ECG diagnostic criteria of the LIFE study to diagnose LVH. LVH on ECG was found to be a risk factor for stroke as well as a predictor of stroke, even in normotensive individuals. 21 The participants were aged from 40 to 69 years, and the results showed that the Cornell product and a Sokolow-Lyon voltage of >38 mm were useful diagnostic criteria, even in middle-aged Japanese participants. Our study showed that a Sokolow-Lyon voltage of >35 mm was a significant risk factor in hypertensive patients 65 years or older (mean age, 73.5 years). Advanced age might have therefore lowered the threshold voltage for the diagnosis of LVH. 22 In the present study as well, patients were stratified into 2 groups by age: younger elderly aged <75 years and older elderly aged ≥75 years. As the study was not designed to directly evaluate the age-related decrease in threshold JISSHO S et al.
voltage, the hazard ratio for the occurrence of events was considered as the hazard ratio for LVH. When a threshold value of 35 mm was used for LVH, the hazard ratio for the occurrence of events was 1.051 (P=0.1576) in the younger elderly and 2.298 (P=0.0004) in the older elderly. When a threshold value of 40 mm was used, the hazard ratio for the occurrence of events was 2.106 (P=0.0216) in the younger elderly and 2.725 (P=0.0002) in the older elderly. These results showed that there was an age-related increase in hazard ratio for the occurrence of events. The results of the ROC analysis ( Table 4 ) also showed that the optimal cutoff value for the Sokolow-Lyon voltage associated with the occurrence of events in the elderly was lower. In a comparison between patients aged <75 years and those aged ≥75 years with the same voltage, the sensitivity increased with age, suggesting that the threshold might decrease with age.
The guidelines proposed by the European Society of Hypertension and the European Society of Cardiology (ESH/ESC 2007) 23 recommend that the Cornell product and Sokolow-Lyon voltage, confirmed to be useful for the ECG diagnosis of LVH in the LIFE study (a randomized controlled trial), should be used for the routine ECG diagnosis of LVH. Furthermore, the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in the United States (JNC 7) 24 and the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) 25 recommended that LVH should be routinely diagnosed on ECG. In our study, the risk of cardiovascular events in elderly patients with hypertension increased by ≥2-fold when the Sokolow-Lyon voltage was >35 mm, and increased by ≥1.5-fold for each 10 mm (=1 mV) increment in Sokolow-Lyon voltage. These results suggest that routine ECG examinations on an outpatient basis might permit early risk assessment as well as identify increasing risk during long-term follow-up in elderly patients with hypertension.
Elderly patients are characterized by complex clinical characteristics associated with multiple chronic diseases ('multimorbidity'). [26] [27] [28] It is therefore important to consider factors such as gender, age, smoking, diabetes mellitus, and disease history as ascertained by clinical interviews before starting antihypertensive treatment in elderly patients with hypertension. More importantly, measures to prevent cardiovascular events should be taken on the basis of ECG findings.
Study Limitations
This study had several limitations. ECG was scheduled to be performed 2 times, once at study entry and once on completion of the study. However, because the participants were outpatients, follow-up became difficult after patients were admitted for cardiovascular events, and data on ECG and blood pressure often could not be obtained; consequently, changes in electrocardiographic variables and blood pressure could not be calculated for all patients with events.
Although 4,418 patients were enrolled in JATOS, LVH was evaluated by ECG in only 3,230. In the other 1,188 patients, the quality of the ECG data was poor because they were sent by facsimile; for example, the grids of plots were unclear, ECG images were magnified by an unknown scale, and data from some of the 12 leads were missing.
Conclusions
In elderly hypertensive patients, LVH diagnosed by SokolowLyon voltage at the start of antihypertensive treatment is a risk factor for cardiovascular events, independent of blood pressure.
